- Investing.com
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Market Potential | With a $13 price target from Barclays, Tango's success in upcoming trials could attract partnerships or acquisition interest from major pharmaceutical companies |
Financial Outlook | Despite negative EPS forecasts, Tango boasts a strong balance sheet with extended cash runway into 2027, demonstrating effective resource management |
Clinical Milestones | Anticipate crucial Phase 1 expansion trial results for pancreatic and lung cancers, with potential to significantly impact stock performance and market position |
Precision Oncology | Tango Therapeutics pioneers innovative cancer treatments, focusing on PRMT5 and CoREST complex inhibitors to exploit genetic vulnerabilities in cancer cells |
Metrics to compare | TNGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTNGXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −33.8x | −10.1x | −0.5x | |
PEG Ratio | −1.27 | −0.02 | 0.00 | |
Price / Book | 9.9x | 5.0x | 2.6x | |
Price / LTM Sales | 55.1x | 13.0x | 3.2x | |
Upside (Analyst Target) | −14.8% | 75.5% | 47.6% | |
Fair Value Upside | Unlock | −5.7% | 6.1% | Unlock |